Efzimfotase alfa, a next‑generation enzyme replacement therapy from AstraZeneca Rare Disease, produced a clear, statistically significant bone‑health signal in treatment‑naïve children and showed more variable but promising effects in adolescents and adults—especially those whose HPP began in childhood. The trials point to biweekly, lower‑volume subcutaneous dosing, good tolerability, and the need for subgroup‑specific decisions in adult patients.
What the Phase III program actually showed
The global Phase III program enrolled 196 patients across 22 countries in three randomized trials—MULBERRY (treatment‑naïve children 2 to <12 years), CHESTNUT (pediatric patients switching from asfotase alfa/Strensiq), and HICKORY (adolescents and adults). In MULBERRY, efzimfotase alfa achieved statistically significant and clinically meaningful improvements in radiographic bone scoring (RGI‑C and RSS) at 25 weeks in treatment‑naïve children. CHESTNUT demonstrated that children switching from the first‑generation enzyme replacement maintained bone health and tolerated the new therapy well. HICKORY did not meet its overall primary endpoint (6‑minute walk test, 6MWT) versus placebo because of unexpectedly strong placebo responses in some adult‑onset patients, but subgroup analyses showed nominally significant mobility and pain benefits among adolescents and adults with pediatric‑onset HPP.
Why those differences matter for real patients
Efzimfotase alfa’s most robust, unambiguous signal is in pediatric, treatment‑naïve HPP: radiographic scores improved by 25 weeks, which creates a concrete threshold clinicians can use when evaluating early response. For patients who switched from asfotase alfa in CHESTNUT, maintenance of bone status and acceptable tolerability suggest the practical advantage of lower injection volume and less frequent dosing without losing prior gains. In adults, the HICKORY results illustrate heterogeneity: adult‑onset HPP participants produced large placebo responses that masked a group‑level drug effect, while the pediatric‑onset subset did show meaningful functional improvement. That pattern implies a decision lens: adult treatment should factor in age at disease onset, baseline function, and willingness to track objective measures (6MWT, 30‑second sit‑to‑stand) and biomarkers—rather than assuming uniform benefit across all adults with HPP.
Safety, dosing logistics, and head‑to‑head practical comparison
Across trials and an earlier Phase I dose‑escalation study, efzimfotase alfa was generally well tolerated. The Phase I work reported a ~6‑day half‑life, dose‑dependent reductions in plasma biomarkers (PLP and inorganic pyrophosphate), mostly mild injection‑site reactions, and no neutralizing antibodies detected. Clinically, efzimfotase alfa is dosed subcutaneously every two weeks with lower injection volumes than first‑generation therapy, which may reduce treatment burden for children who require lifelong administration.
| Trial | Population | Primary endpoint | Key outcome |
|---|---|---|---|
| MULBERRY | Treatment‑naïve children (2–<12 yrs) | Radiographic indices (RGI‑C, RSS) at 25 weeks | Statistically significant, clinically meaningful bone‑health improvements |
| CHESTNUT | Children switching from asfotase alfa | Maintenance of bone health and safety | Maintained benefits; favorable safety/tolerability |
| HICKORY | Adolescents and adults | 6‑minute walk test (6MWT) | Numerical improvement overall (not statistically significant); pediatric‑onset subgroup showed nominally significant functional gains |
| Phase I | Healthy volunteers / adults (dose‑escalation) | PK, safety, biomarkers | ~6‑day half‑life, PLP/PPi reductions, mild local reactions, no neutralizing antibodies |
Practically, the faster radiographic gains in MULBERRY set a short‑term checkpoint (25 weeks) for pediatric response; in adults, expect a longer, subgroup‑sensitive assessment window and plan objective functional testing rather than relying solely on symptom reports.
Choosing, monitoring, and stopping: practical checkpoints for clinicians and patients
Decisions about starting efzimfotase alfa should weigh age at HPP onset, prior enzyme replacement history, baseline mobility, and the patient’s willingness to use biweekly subcutaneous injections. For treatment‑naïve children, the MULBERRY 25‑week improvement provides a clear early threshold to continue therapy. For adults—especially adult‑onset cases—start only with a plan to measure objective endpoints (6MWT, sit‑to‑stand) and biomarkers (PLP, PPi) and to re‑evaluate at prespecified intervals, because group‑level efficacy was not uniform in HICKORY.
Q&A: timing, who benefits most, and stop signals
Who is the clearest candidate? Treatment‑naïve children (2–<12 years) showed the most robust, statistically significant bone improvements at 25 weeks in MULBERRY.
When should clinicians reassess benefit? For children, 25 weeks is a meaningful checkpoint; for adults, reassess functional endpoints and biomarkers at regular intervals (for example, every 3–6 months) because subgroup responses vary.
What would prompt stopping or switching? Lack of objective improvement (radiographic scores for children; 6MWT or sit‑to‑stand plus biomarker trends in adults), intolerable adverse reactions, or new safety signals would all justify pausing or changing therapy—especially since regulatory guidance and detailed subgroup analyses are still pending.